Xencor Inc balance sheet
At the end of fiscal 2025, Xencor Inc had total assets of $875m, total liabilities of $240m and shareholders' equity of $636m. It held $54.1m in cash against $120m of debt.
Balance sheet
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15 | 17 | 26 | 50 | 164 | 143 | 54 | 54 | 41 | 54 | 45 |
| Receivables | 9 | 1 | 10 | 22 | 11 | 66 | 29 | 24 | 61 | 29 | 42 |
| Total current assets | 142 | 231 | 316 | 558 | 638 | 424 | 675 | 636 | 578 | 600 | 523 |
| Total assets | 429 | 390 | 577 | 670 | 703 | 838 | 846 | 965 | 952 | 875 | 725 |
| Accounts payable | 4 | 7 | 4 | 10 | 9 | 14 | 10 | 14 | 17 | 11 | 13 |
| Deferred revenue (current) | 96 | 60 | 40 | 45 | 93 | 37 | 30 | 0 | 0 | — | — |
| Total current liabilities | 106 | 73 | 54 | 67 | 121 | 71 | 64 | 74 | 87 | 96 | 82 |
| Short-term debt | — | — | — | — | — | — | 0 | 28 | 48 | 43 | 27 |
| Long-term debt | — | — | — | — | — | — | 0 | 162 | 115 | 76 | 78 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 189 | 164 | 120 | 105 |
| Total liabilities | 115 | 74 | 55 | 77 | 131 | 105 | 119 | 303 | 278 | 240 | 222 |
| Shareholders' equity | 338 | 316 | 522 | 593 | 572 | 734 | 727 | 662 | 678 | 636 | 503 |
| Non-controlling interests and other (assets − liabilities − equity) | −24 | — | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 47m | 47m | 56m | 57m | 58m | 59m | 60m | 61m | 70m | 72m | 74m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 26 | 61 | 38 | 48 | 22 | 29 | 12 | 42 |
| Total current assets | 590 | 578 | 521 | 513 | 518 | 600 | 483 | 523 |
| Total assets | 1,000 | 952 | 905 | 879 | 869 | 875 | 737 | 725 |
| Accounts payable | 19 | 17 | 16 | 19 | 9 | 11 | 8 | 13 |
| Deferred revenue (current) | 0 | 0 | — | — | — | — | — | — |
| Total current liabilities | 91 | 87 | 88 | 96 | 86 | 96 | 73 | 82 |
| Short-term debt | 44 | 48 | 53 | 50 | 45 | 43 | 26 | 27 |
| Long-term debt | 128 | 115 | 102 | 95 | 88 | 76 | 82 | 78 |
| Total debt | 173 | 164 | 154 | 145 | 133 | 120 | 109 | 105 |
| Total liabilities | 294 | 278 | 265 | 259 | 243 | 240 | 221 | 222 |
| Shareholders' equity | 709 | 678 | 640 | 620 | 625 | 636 | 516 | 503 |
| Shares outstanding | 70m | 70m | 71m | 71m | 71m | 72m | 74m | 74m |
Compare with peers
- Kymera Therapeutics, Inc. balance sheet
- Septerna, Inc. balance sheet
- Agios Pharmaceuticals, Inc. balance sheet
- ARS Pharmaceuticals, Inc. balance sheet
- Arcus Biosciences, Inc. balance sheet
Head to head: KYMR vs XNCRSEPN vs XNCRAGIO vs XNCRSPRY vs XNCR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies